Imeglimin is a promising new oral antihyperglycemic agent, which has been studied in 39 clinical trials as a possible mono-or add-on therapy to lower fasting plasma glucose and 40 improve hemoglobin A 1c (1)(2)(3) 9). Imeglimin was shown to improve both fasting and 41 postprandial glycemia and to increase insulin secretion in response to glucose during a 42 hyperglycemic clamp after 1-week treatment in type 2 diabetic patients. However, 43
Introduction 54
Imeglimin is a new oral antihyperglycemic agent, which has been studied in clinical trials 55 as a possible mono-or add-on therapy to lower fasting plasma glucose and improve 56 hemoglobin A 1c (2, 3, 9) . Imeglimin was shown to improve both fasting and postprandial 57 glycemia (1), and increase insulin secretion in response to glucose during a 58 hyperglycemic clamp after 1-week treatment in type 2 diabetic patients (8) . 59
Improvements in glucose tolerance have been reported in both humans and rodentstreated with imeglimin but have been ascribed to multiple mechanisms: lower hepatic 61 lipids (12), improved liver and muscle insulin signaling (12), and improved β-cell function 62 (3, 12). However, prior studies have not utilized the gold-standard technique to evaluate 63 hepatic insulin sensitivity, the hyperinsulinemic-euglycemic clamp. Of note, although the 64 mechanism of action of imeglimin has been ascribed at least in part to improved insulin 65 sensitivity (12), improved insulin sensitivity would be expected to result in reductions in 66 plasma insulin concentrations, not the increases that have been noted in multiple 67 human (8, 9) and rodent (12) studies. Additionally, previous papers have not included in 68 vitro studies to determine whether imeglimin increases glucose-stimulated insulin 69 secretion directly or indirectly. In addition, most of the prior studies performed with 70 imeglimin were long-term treatment studies (months-long), which do not allow 71 researchers to identify the first beneficial effects of the drug. To this end, we performed 72 intraperitoneal glucose tolerance tests (GTT) and hyperinsulinemic-euglycemic clamps 73 in chow-and high fat fed rats treated with imeglimin for 2 weeks, thereby conclusively 74 demonstrating the mechanism by which imeglimin improves glycemia in the high fat fed 75 rat using a comprehensive toolkit of gold-standard in vitro and in vivo techniques. 76
Furthermore, we assessed glucose-stimulated insulin secretion in isolated rat islets and 77 identified a direct, glucose-dependent, amplifying mechanism of action that would 78 explain the absence of hypoglycemia when used at recommended pharmacologic 79 concentrations in humans. 80
81
In the clamp studies, rats were again studied after a total of four weeks of diet 106 feeding, during the last two of which they were treated with imeglimin (150 mg/kg twice 107 daily in peanut butter, or peanut butter vehicle). Following an overnight fast, a 120 min 108 basal infusion of [6, H 2 ] glucose (1 mg/[kg-min] prime for 5 min, followed by a 0.25 109 mg/[kg-min] continuous infusion) was administered, with 200 μl whole blood taken after 110 100, 110, and 120 min of infusion to measure glucose turnover as described below. manufacturer's instructions, 10 mM HEPES, 4 mM glutamine, 0.2% fatty acid free BSA 141 and 2.5 mM glucose). Eighty islets for each condition were perifused at a rate of 100 142 μl/min on an 8 or 12-channel BioRep Technologies perifusion device (Miami, FL). Islets 143 were equilibrated on the instrument in basal (2.5 mM) glucose perifusion media with or 144 without imeglimin (100 μM) for 45 minutes prior to sample collection in a 5% CO 2 /95% 145 air, 37 o C constant environment. For static secretion assays, intact islets were dispersed 146 using accutase (Gibco) and re-aggregated to form single pseudo-islet 147 aggregates. Following dispersion into single cells, the cell suspension was seeded at 148 5,000 cells per well of a 96-well V-bottom plate and cultured under the same conditions 149 as the intact islets. Pseudo-islet aggregates formed 12-24hrs after incubation at 37 o C 150 5% CO 2 /95% air. Rat insulin was measured in the perifusate/incubation media using ahigh range rat insulin ELISA (ALPCO, Salem, NH) and normalized to total islet DNA 152 concentration using Quant-it PicoGreen dsDNA Assay Kit (Life Technologies, Carlsbad, 153 CA). Secretagogues included the glucokinase activator (MK-0941), tolbutamide, 154 exendin-4 (Tocris), L-leucine, forskolin, and monomethyl ester of succinic acid (SAME) 155 at the indicated concentrations. 156
157

Results
158
Imeglimin treatment does not alter body composition or energetics 159
Metabolic cage analysis revealed no difference in any parameter studied in chow-or 160 high fat fed mice treated for one week with imeglimin, with the exception of food intake, 161 which was modestly lower in imeglimin treated mice ( Fig. 1-2) . Similarly, in chow-and 162 high fat fed (HFD) mice treated chronically (3-5 weeks) with imeglimin, there were no 163 differences seen in body composition, food and water intake, or energetics compared to 164 vehicle-treated controls (Fig. 3-4) . 165
166
Imeglimin-treated rats exhibit improved glucose tolerance due to increased insulin 167 secretion in vivo 168
In chow fed rats, 2 weeks of imeglimin treatment resulted in a striking improvement in 169 glucose tolerance, with lower plasma glucose concentrations throughout the GTT (Fig.  170 5A-B). Imeglimin-treated mice exhibited 30-100% increases in insulin secretion at each 171 time point during the GTT, with more than a doubling in the insulin area under the curve 172 during the GTT (Fig. 5C-D) . These results were replicated in high fat fed (HFD) rats:imeglimin improved glucose tolerance by increasing insulin secretion throughout a GTT 174 after a two-week treatment period (Fig. 6A-D) . 175
176
Imeglimin does not alter insulin sensitivity in chow-or high fat fed rats 177
The improvements in glucose tolerance observed in imeglimin-treated rats were not 178 associated with hepatic AMPK activation in chow fed rats; however, we observed a 50% 179 reduction in ACC phosphorylation as predicted by imeglimin-treated rats' higher plasma 180 insulin concentrations ( Fig. 7A-B ) (13). In order to determine whether imeglimin 181 treatment was associated with improved hepatic or peripheral muscle insulin sensitivity, 182
we performed hyperinsulinemic-euglycemic clamps and observed no difference in the 183 glucose infusion rate required to maintain euglycemia, in basal or clamped hepatic 184 glucose production, or in peripheral muscle glucose disposal during the clamp (Fig. 7C-185 G). Similarly in HFD rats, there were no differences in hepatic or muscle insulin 186 sensitivity as indicated by the absence of any differences in glucose infusion rate, 187 hepatic glucose production, or muscle glucose uptake after 2 weeks of imeglimin 188 treatment ( Fig. 8A-E) . 189
190
Imeglimin amplifies rather than triggers insulin secretion. 191
In order to determine whether imeglimin directly stimulates beta-cell insulin secretion, 192
we measured glucose-stimulated insulin secretion by isolated islet perifusion and static 193 incubations. Adding imeglimin to previously untreated rat islets at 100 μM, a dose 194 previously demonstrated to stimulate GSIS (12), caused an immediate increase in 195 glucose-stimulated insulin secretion (Fig. 9A ). An area under the curve analysisidentified the mitochondrial metabolism-dependent second phase of insulin secretion 197 accounting for the bulk of the increase (Fig. 9B) . In comparison to other islet 198 secretagogues, insulin secretion appeared to be dependent upon glucose metabolism 199 up to a concentration of 1 mM imeglimin (Fig. 9C) . The glucose dependency displayed a 200 graded amplifying behavior except at concentrations >5 mM (well above its therapeutic 201 target range) where it triggered insulin release even at low glucose ( Fig. 9D,E) . To 202 determine whether imeglimin was dependent on glycolytic and/or mitochondrial 203 metabolism, islet perifusions were performed using obligate mitochondrial fuels such as 204 leucine and succinate ( suggesting that the lack of an observed difference in the perifusion could be attributed 211 to having reached maximal insulin release (Fig. 9H ). Like leucine, the methyl ester of 212 succinate (SAME) has both anaplerotic and oxidative metabolism but showed only a 213 trend toward being amplified by imeglimin (Fig. 9I,J) . Taken together, these data imply 214 that the primary mechanism of action of imeglimin is via an amplification of 215 mitochondrial metabolism-dependent signals that stimulate insulin release. 216 217 218
Discussion 220
The attractive safety and efficacy profile of imeglimin in poorly controlled diabetic 221 patients raises the question of how and why it is so safe and effective. Improved 222 glucose tolerance in rodents suggests the possibility of a phenotype in the beta-cell (8); 223 however, definitive studies had not yet been performed to assess hepatic and peripheral 224 muscle insulin sensitivity or whole-body energetics. We determined that short-term 225 imeglimin treatment modulates glucose-stimulated insulin secretion (GSIS) in isolated 226 islets and in vivo in rats during a GTT without altering hepatic or peripheral insulin 227 sensitivity, AMPK activity, or energetics. The lack of any difference in hepatic insulin 228 sensitivity in high fat fed rats using the gold-standard technique, the hyperinsulinemic-229 euglycemic clamp, shows that after 2 weeks of treatment, imeglimin's benefit on 230 glucose tolerance in this HFD rat model is due to its ability to increase glucose-231 stimulated insulin secretion. This result contrasts with the improvement in insulin 232 sensitivity shown by Vial et al. (12) in the high fat, high sucrose diet mouse model 233 (HFHSD) and by Fouqueray et al (1) in streptozotocin-treated diabetic rats. These 234 differences could be explained by the difference in treatment duration (2 weeks in the 235 present study vs. 6-7 weeks in the previous studies) and/or by differences in imeglimin 236 effects in the models. Imeglimin decreased liver lipid content in HFHSD mice by 30% 237 (12) but had no effect on liver triglycerides in the present study (data not shown). 238
Treatment of isolated rodent islets with imeglimin acutely potentiated insulin 239 secretion indicating that there is a primary and direct effect of the compound on intact 240 islets. Similarly, following the treatment of healthy rodents in vivo for two weeks there 241 was noticeable improvement in insulin secretion consistent with a primary islet effect. It 242 is not surprising and perhaps anticipated that thereare also potential secondary benefits 243 following the improved glucose homeostasis from augmented insulin secretion. These 244 might include improvements in insulin sensitivity after a longer treatment (6 weeks) as 245 observed in a high fat rat model of insulin resistance. It is also possible that chronic 246 imeglimin treatment may secondarily improve liver and muscle insulin sensitivity in 247 diabetic rodents and patients with type 2 diabetes through reversal of glucose toxicity 248 (10). 249
In isolated islet perifusions from healthy rats, imeglimin displayed a potent 250 metabolism-dependent stimulation that resembled more the amplifying effect observed 251 with cell surface receptors (e.g., GLP-1R or GPR40) rather than triggering by increasing 252 metabolism or directly closing K ATP channels (e.g., glucokinase activators or 253 sulfonylureas) (5, 6). This pharmacologic behavior links the enhanced insulin secretion 254 to metabolic coupling factors. As such, the amplifying effect is minimal when on the low 255 end of the physiologic range. This may help explain imeglimin's observed efficacy 256 without causing hypoglycemia in humans. As glucose levels climb, there is a 257 progressive increase in secretion as would be needed to re-establish homeostasis 258 following a meal. By only acting when glucose levels are high, the intermittent 259 responsivity prevents basal hyperinsulinism and potentially allows the beta-cell more of 260 a chance to rest between challenges. These may afford a long-term advantage of this 261 novel class of oral agents to protect and/or preserve islet health. 262
Future studies will be needed to identify the receptor and/or pathway(s) through 263 which this compound acts. In particular, given that both anaplerotic and oxidative 264 mitochondrial metabolism are coupled to insulin secretion, it will be important todetermine if imeglimin's action is dependent on one and/or the other (7, 11) . 266
Regardless, here we demonstrate that the primary mechanism of imeglimin appears to 267 be via islet amplification rather than improving insulin sensitivity in the high fat fed rat. 268
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